Overview
The purpose of this study is to evaluate if treatment with a siplizumab-based regimen can induce allogeneic tolerance in liver transplant recipients.
Eligibility
Inclusion Criteria:
- Able to understand the study requirements and provide written informed consent before and study assessment is performed
- Adult subjects aged 18-70 receiving an ABO compatible deceased donor liver transplant
- Male study subjects willing to maintain barrier contraception (condom) and agree not to father a child until 12 weeks after the last dose of MMF
Exclusion Criteria:
- Pregnant or nursing (lactating) women
- Subjects with a history of TB or latent TB infection
- Subjects with a history of cancer